Leukemia cutis

Last updated
Leukemia cutis
Specialty Dermatology

Leukemia cutis is the infiltration of neoplastic leukocytes or their precursors into the skin resulting in clinically identifiable cutaneous lesions. [1] This condition may be contrasted with leukemids, which are skin lesions that occur with leukemia, but which are not related to leukemic cell infiltration. [1] [2] Leukemia cutis can occur in most forms of leukemia, including chronic myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, acute myeloid leukemia, and prolymphocytic leukemia. [3]

Contents

Signs and symptoms

The clinical appearance of leukemia cutis varies, with the most common lesions being erythematous to violaceous papules or nodules (60%), followed by infiltrating plaques, generalized cutaneous eruption, and erythroderma. [4] Oftentimes, they have no symptoms. [5] Usually having a solid or rubbery consistency, the nodules might turn purpuric in patients who are thrombocytopenic. [4]

Unusual presentations include those that resemble ulcers, stasis dermatitis, guttate psoriasis, and figurate erythemas. Leukemia cutis has also been reported to localize to injuries, intravenous catheters, herpes lesions, and recent surgical procedures. [4]

Causes

Leukemia cutis may develop concurrently with the diagnosis of systemic leukemia, come first, or come later. Most cases of leukemia cutis occur in the context of an existing leukemia (44–77%) or at the time of systemic leukemia presentation (23–44%). [4] On rare occasions, leukemia cutis may occur before leukemia in the bone marrow or peripheral blood becomes observable. [6]

Leukemia cutis is linked to a number of gene abnormalities, such as chromosome 8 numerical anomalies, translocation (8; 21) (q22; q22), and inversion (16) (p13; q22). [7] [8]

Mechanism

Leukemic skin involvement's pathogenic mechanism is poorly understood. [9] Nonetheless, it's thought that chemokine receptors, adhesion molecules, and the genetic features of leukemia all have an impact. [10] Adhesion molecules, specifically chemokine integrin, may have a role in the migration of leukemic cells into the skin through processes known as skin-selective homing. [11] [12] Adhesion molecules and chemokine receptors may also have significant effects. On the dermal post-capillary venules, TARC (thymus- and activation-regulated chemokine)/CCL17 (CC chemokine ligand 17) and/or E-selectin may interact with the cutaneous leucocyte-associated antigen (CLA) receptor and CC chemokine receptor 4 (CCR4) on the leukemic cells. Leukemic cell migration and binding into the dermis may be facilitated by this process. Additionally, integrins and endothelial-bound chemokines may interact to promote leukemic cell migration into the dermis. [9]

Diagnosis

Leukemia cutis is diagnosed by looking at the morphologic pattern of skin infiltration, cytologic characteristics, and most importantly the tumor cells' immunophenotype. The diagnosis is frequently confirmed by correlation with peripheral blood and bone marrow results as well as clinical data. [10]

Treatment

Leukemia cutis is a localized symptom of a systemic underlying disease that requires systemic therapy tailored to the individual subtype of leukemia. Hematologic remission typically happens in tandem with a full or partial response to cutaneous infiltrations in the majority of individuals. [9] Local radiotherapy, however, may be employed in patients with resistant leukemia cutis or recurrent skin infiltration. [13] The treatment of refractory cutaneous leukemia has led to the proposal of simultaneous integrated boost with helical arc radiotherapy of total skin (HEARTS) for cutaneous symptoms. [14]

Outlook

The prognosis is poor, with many patients suffering from additional extramedullary diseases and low survival rates. Most patients pass away months after being diagnosed. Patients without skin lesions who have acute myelogenous leukemia had a 30% survival rate after two years, but those with skin lesions have a 6% survival rate, which indicates an unfavorable prognosis for leukemia cutis. [4]

Epidemiology

Leukemia cutis can occur anywhere between 2% and 30% of the time, depending on the underlying leukemia diagnosis. [9]

See also

Related Research Articles

<span class="mw-page-title-main">Mastocytosis</span> Medical condition

Mastocytosis, a type of mast cell disease, is a rare disorder affecting both children and adults caused by the accumulation of functionally defective mast cells and CD34+ mast cell precursors.

<span class="mw-page-title-main">Tumors of the hematopoietic and lymphoid tissues</span> Tumors that affect the blood, bone marrow, lymph, and lymphatic system

Tumors of the hematopoietic and lymphoid tissues or tumours of the haematopoietic and lymphoid tissues are tumors that affect the blood, bone marrow, lymph, and lymphatic system. Because these tissues are all intimately connected through both the circulatory system and the immune system, a disease affecting one will often affect the others as well, making aplasia, myeloproliferation and lymphoproliferation closely related and often overlapping problems. While uncommon in solid tumors, chromosomal translocations are a common cause of these diseases. This commonly leads to a different approach in diagnosis and treatment of hematological malignancies. Hematological malignancies are malignant neoplasms ("cancer"), and they are generally treated by specialists in hematology and/or oncology. In some centers "hematology/oncology" is a single subspecialty of internal medicine while in others they are considered separate divisions. Not all hematological disorders are malignant ("cancerous"); these other blood conditions may also be managed by a hematologist.

<span class="mw-page-title-main">Lichen planus</span> Human chronic inflammatory disease

Lichen planus (LP) is a chronic inflammatory and autoimmune disease that affects the skin, nails, hair, and mucous membranes. It is not an actual lichen, but is named for its appearance. It is characterized by polygonal, flat-topped, violaceous papules and plaques with overlying, reticulated, fine white scale, commonly affecting dorsal hands, flexural wrists and forearms, trunk, anterior lower legs and oral mucosa. The hue may be gray-brown in people with darker skin. Although there is a broad clinical range of LP manifestations, the skin and oral cavity remain as the major sites of involvement. The cause is unknown, but it is thought to be the result of an autoimmune process with an unknown initial trigger. There is no cure, but many different medications and procedures have been used in efforts to control the symptoms.

<span class="mw-page-title-main">Calcinosis cutis</span> Medical condition in which calcium deposits form in the skin

Calcinosis cutis is an uncommon condition marked by calcium buildup in the skin and subcutaneous tissues. Calcinosis cutis can range in intensity from little nodules in one area of the body to huge, crippling lesions affecting a vast portion of the body. Five kinds of the condition are typically distinguished: calciphylaxis, idiopathic calcification, iatrogenic calcification, dystrophic calcification, and metastatic calcification.

<span class="mw-page-title-main">Adult T-cell leukemia/lymphoma</span> Human disease

Adult T-cell leukemia/lymphoma is a rare cancer of the immune system's T-cells caused by human T cell leukemia/lymphotropic virus type 1 (HTLV-1). All ATL cells contain integrated HTLV-1 provirus further supporting that causal role of the virus in the cause of the neoplasm. A small amount of HTLV-1 individuals progress to develop ATL with a long latency period between infection and ATL development. ATL is categorized into 4 subtypes: acute, smoldering, lymphoma-type, chronic. Acute and Lymphoma-type are known to particularity be aggressive with poorer prognosis.

<span class="mw-page-title-main">Myeloid sarcoma</span> Medical condition

A myeloid sarcoma is a solid tumor composed of immature white blood cells called myeloblasts. A chloroma is an extramedullary manifestation of acute myeloid leukemia; in other words, it is a solid collection of leukemic cells occurring outside of the bone marrow.

<span class="mw-page-title-main">Mycosis fungoides</span> Most common form of cutaneous T-cell lymphoma

Mycosis fungoides, also known as Alibert-Bazin syndrome or granuloma fungoides, is the most common form of cutaneous T-cell lymphoma. It generally affects the skin, but may progress internally over time. Symptoms include rash, tumors, skin lesions, and itchy skin.

<span class="mw-page-title-main">Febrile neutrophilic dermatosis</span> Medical condition

Sweet syndrome (SS), or acute febrile neutrophilic dermatosis, is a skin disease characterized by the sudden onset of fever, an elevated white blood cell count, and tender, red, well-demarcated papules and plaques that show dense infiltrates by neutrophil granulocytes on histologic examination.

<span class="mw-page-title-main">Acute myeloid leukemia</span> Cancer of the myeloid line of blood cells

Acute myeloid leukemia (AML) is a cancer of the myeloid line of blood cells, characterized by the rapid growth of abnormal cells that build up in the bone marrow and blood and interfere with normal blood cell production. Symptoms may include feeling tired, shortness of breath, easy bruising and bleeding, and increased risk of infection. Occasionally, spread may occur to the brain, skin, or gums. As an acute leukemia, AML progresses rapidly, and is typically fatal within weeks or months if left untreated.

<span class="mw-page-title-main">CCL17</span> Mammalian protein found in Homo sapiens

CCL17 is a powerful chemokine produced in the thymus and by antigen-presenting cells like dendritic cells, macrophages, and monocytes. CCL17 plays a complex role in cancer. It attracts T-regulatory cells allowing for some cancers to evade an immune response. However, in other cancers, such as melanoma, an increase in CCL17 is linked to an improved outcome. CCL17 has also been linked to autoimmune and allergic diseases.

Biphenotypic acute leukaemia (BAL) is an uncommon type of leukemia which arises in multipotent progenitor cells which have the ability to differentiate into both myeloid and lymphoid lineages. It is a subtype of "leukemia of ambiguous lineage".

<span class="mw-page-title-main">Mast cell leukemia</span> Medical condition

Mast cell leukemia is an extremely aggressive subtype of acute myeloid leukemia that usually occurs de novo but can, rarely, evolve from transformation of chronic myeloid leukemia into the more aggressive acute myeloid leukemia. In a small proportion of cases, acute mast cell leukemia may evolve from a more progressive form of systemic mastocytosis. The diagnosis of acute mast cell leukemia by the WHO criteria includes the requirement for a prevalence of 20% neoplastic mast cells in marrow and 10% in blood. If the mast cells represent less than 10% of blood cells, the tumor is called "aleukemic" mast cell leukemia.

Tumid lupus erythematosus is a rare, but distinctive entity in which patients present with edematous erythematous plaques, usually on the trunk.

Alopecia mucinosa, also known as Follicular mucinosis, Mucinosis follicularis, Pinkus' follicular mucinosis, and Pinkus' follicular mucinosis–benign primary form, is a skin disorder that generally presents, but not exclusively, as erythematous plaques or flat patches without hair primarily on the scalp, neck and face. This can also be present on the body as a follicular mucinosis and may represent a systemic disease.

<span class="mw-page-title-main">Blastic plasmacytoid dendritic cell neoplasm</span> Medical condition

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy. It was initially regarded as a form of lymphocyte-derived cutaneous lymphoma and alternatively named CD4+CD56+ hematodermic tumor, blastic NK cell lymphoma, and agranular CD4+ NK cell leukemia. Later, however, the disease was determined to be a malignancy of plasmacytoid dendritic cells rather than lymphocytes and therefore termed blastic plasmacytoid dendritic cell neoplasm. In 2016, the World Health Organization designated BPDCN to be in its own separate category within the myeloid class of neoplasms. It is estimated that BPDCN constitutes 0.44% of all hematological malignancies.

<span class="mw-page-title-main">Sebaceous carcinoma</span> Medical condition

Sebaceous carcinoma, also known as sebaceous gland carcinoma (SGc), sebaceous cell carcinoma, and meibomian gland carcinoma is an uncommon malignant cutaneous tumor. Most are typically about 1.4 cm at presentation. SGc originates from sebaceous glands in the skin and, therefore, may originate anywhere in the body where these glands are found. SGc can be divided into 2 types: periocular and extraocular. The periocular region is rich in sebaceous glands making it a common site of origin. The cause of these lesions in the vast majority of cases is unknown. Occasional cases may be associated with Muir-Torre syndrome. SGc accounts for approximately 0.7% of all skin cancers, and the incidence of SGc is highest in Caucasian, Asian, and Indian populations. Due to the rarity of this tumor and variability in clinical and histological presentation, SGc is often misdiagnosed as an inflammatory condition or a more common neoplasm. SGc is commonly treated with wide local excision or Mohs micrographic surgery, and the relative survival rates at 5 and 10 years are 92.72 and 86.98%, respectively.

<span class="mw-page-title-main">Blueberry muffin baby</span> Medical condition

Blueberry muffin baby, also known as extramedullary hematopoiesis, describes a newborn baby with multiple purpura, associated with several non-cancerous and cancerous conditions in which extra blood is produced in the skin. The bumps range from one to seven mm, do not blanch and have a tendency to occur on the head, neck and trunk. They often fade by three to six weeks after birth, leaving brownish marks. When due to a cancer, the bumps tend to be fewer, firmer and larger.

Primary cutaneous anaplastic large cell lymphoma belongs to the group of cutaneous processes that are CD30+ lymphoproliferative and are characterized by autoregressive, recurrent, single or multifocal ulcerating nodules. Single or localized nodules, papules, or plaques are present in the majority of patients. However, a patient may have more than one lesion in up to 20% of cases.

Leukemids are nonspecific skin lesions that occur with leukemia which are not related to leukemic cell infiltration. This condition may be contrasted with leukemia cutis, which is the infiltration of neoplastic leukocytes or their precursors into the skin resulting in clinically identifiable cutaneous lesions.

Lymphocyte-variant hypereosinophilia is a rare disorder in which eosinophilia or hypereosinophilia is caused by an aberrant population of lymphocytes. These aberrant lymphocytes function abnormally by stimulating the proliferation and maturation of bone marrow eosinophil-precursor cells termed colony forming unit-eosinophils or CFU-Eos.

References

  1. 1 2 James, William Daniel; Berger, Timothy G.; Elston, Dirk M. (2006). Andrews' Diseases of the Skin: clinical Dermatology . Saunders Elsevier. pp.  744–5. ISBN   978-0-7216-2921-6.
  2. ↑ Rapini, Ronald P.; Bolognia, Jean L.; Jorizzo, Joseph L. (2007). Dermatology: 2-Volume Set. St. Louis: Mosby. p. 1892. ISBN   978-1-4160-2999-1.
  3. ↑ Leukemia Cutis at eMedicine
  4. 1 2 3 4 5 Rao, AngooriG; Danturty, Indira (2012). "Leukemia cutis". Indian Journal of Dermatology. Medknow. 57 (6): 504. doi: 10.4103/0019-5154.103086 . ISSN   0019-5154. PMC   3519272 . PMID   23248383.
  5. ↑ Koizumi, Hiroko; Kumakiri, Masanobu; Ishizuka, Midori; Ohkawara, Akira; Okabe, Sanehiro (1991). "Leukemia Cutis in Acute Myelomonocytic Leukemia: Infiltration to Minor Traumas and Scars". The Journal of Dermatology. Wiley. 18 (5): 281–285. doi:10.1111/j.1346-8138.1991.tb03083.x. ISSN   0385-2407. PMID   1939854. S2CID   19558080.
  6. ↑ Yones, SS; Khorasgani, MG; Iqbal, T; Arrifin, N; Mehta, R; Skibinska, G; Karim, A; Grech, C; Ivanov, G; Khorshid, M (December 2009). "Aleukemic leukemia cutis" (PDF). Egyptian Dermatology Online Journal. 5 (2). Retrieved 9 March 2024.
  7. ↑ Agis, H.; Weltermann, A.; Fonatsch, C.; Haas, O.; Mitterbauer, G.; Müllauer, L.; Schreiber, S.; Schwarzinger, I.; Juretzka, W.; Valent, P.; Jäger, U.; Lechner, K.; Geissler, K. (2002-01-23). "A comparative study on demographic, hematological, and cytogenetic findings and prognosis in acute myeloid leukemia with and without leukemia cutis". Annals of Hematology. Springer Science and Business Media LLC. 81 (2): 90–95. doi:10.1007/s00277-001-0412-9. ISSN   0939-5555. PMID   11907789. S2CID   9364519.
  8. ↑ Kubonishi, Ichiro; Seto, Masao; Murata, Naoaki; Kamioka, Mikio; Taguchi, Hirokuni; Miyoshi, Iaso (1998). "Translocation (10;11)(p13;q13) and MLL Gene Rearrangement in a Case of AML (M5a) with Aggressive Leukemia Cutis". Cancer Genetics and Cytogenetics. Elsevier BV. 104 (1): 28–31. doi:10.1016/s0165-4608(97)00414-7. ISSN   0165-4608. PMID   9648554.
  9. 1 2 3 4 Robak, Ewa; Braun, Marcin; Robak, Tadeusz (2023-11-13). "Leukemia Cutis—The Current View on Pathogenesis, Diagnosis, and Treatment". Cancers. MDPI AG. 15 (22): 5393. doi: 10.3390/cancers15225393 . ISSN   2072-6694. PMC   10670312 . PMID   38001655.
  10. 1 2 Cho-Vega, Jeong Hee; Medeiros, L. Jeffrey; Prieto, Victor G.; Vega, Francisco (2008). "Leukemia Cutis". American Journal of Clinical Pathology. 129 (1): 130–142. doi:10.1309/WYACYWF6NGM3WBRT. ISSN   0002-9173. PMID   18089498.
  11. ↑ Li, Alvin W.; Yin, Emily S.; Stahl, Maximilian; Kim, Tae Kon; Panse, Gauri; Zeidan, Amer M.; Leventhal, Jonathan S. (2017). "The skin as a window to the blood: Cutaneous manifestations of myeloid malignancies". Blood Reviews. Elsevier BV. 31 (6): 370–388. doi:10.1016/j.blre.2017.07.003. ISSN   0268-960X. PMID   28732587.
  12. ↑ Bakst, Richard; Powers, Ann; Yahalom, Joachim (2020). "Diagnostic and Therapeutic Considerations for Extramedullary Leukemia". Current Oncology Reports. 22 (7): 75. doi:10.1007/s11912-020-00919-6. ISSN   1523-3790. PMID   32577912. S2CID   219988937.
  13. ↑ Elsayad, Khaled; Oertel, Michael; Haverkamp, Uwe; Eich, Hans Theodor (2017-01-16). "The effectiveness of radiotherapy for leukemia cutis". Journal of Cancer Research and Clinical Oncology. Springer Science and Business Media LLC. 143 (5): 851–859. doi:10.1007/s00432-016-2338-6. ISSN   0171-5216. PMID   28093639. S2CID   24622600.
  14. ↑ Hsieh, Chen-Hsi; Tien, Hui-Ju; Yu, Yuan-Bin; Wu, Yuan-Hung; Shueng, Pei-Wei; Lu, Yueh-Feng; Wang, Shan-Ying; Wang, Li-Ying (2019). "Simultaneous integrated boost with helical arc radiotherapy of total skin (HEARTS) to treat cutaneous manifestations of advanced, therapy-refractory cutaneous lymphoma and leukemia — dosimetry comparison of different regimens and clinical application". Radiation Oncology. 14 (1): 17. doi: 10.1186/s13014-019-1220-5 . ISSN   1748-717X. PMC   6348688 . PMID   30691490.

Further reading

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.